{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T13:00:57Z","timestamp":1726491657734},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,6]],"date-time":"2016-04-06T00:00:00Z","timestamp":1459900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Egyptian National Cancer Institute"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.jnci.2016.04.003","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T15:57:55Z","timestamp":1462636675000},"page":"141-148","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence"],"prefix":"10.1186","volume":"28","author":[{"given":"Rony","family":"Benson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Supriya","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.K.","family":"Julka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.K.","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"2","key":"10.1016\/j.jnci.2016.04.003_b0005","doi-asserted-by":"crossref","first-page":"e0009","DOI":"10.5041\/RMMJ.10143","article-title":"Head and neck cancers in developing countries","volume":"5","author":"Joshi","year":"2014","journal-title":"Rambam Maimonides Med J"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.003_b0010","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S0022215106002751","article-title":"Analysis of 2167 head and neck cancer patients\u2019 management, treatment compliance and outcomes from a regional cancer centre, Delhi, India","volume":"121","author":"Mohanti","year":"2007","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.jnci.2016.04.003_b0015","article-title":"Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): a meta-analysis of randomized trials","author":"Budach","year":"2015","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.jnci.2016.04.003_b0020","first-page":"6247","article-title":"Induction chemotherapy and sequential concomitant chemo-radiation in locally advanced head and neck cancers: how induction-phase intensity and treatment breaks may impact on clinical outcomes","volume":"35","author":"Franco","year":"2015","journal-title":"Anticancer Res"},{"issue":"12","key":"10.1016\/j.jnci.2016.04.003_b0025","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1634\/theoncologist.2015-0177","article-title":"Balancing safety and efficacy of epidermal growth factor receptor inhibitors in patients with squamous cell carcinoma of the head and neck","volume":"20","author":"Iberri","year":"2015","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.003_b0030","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"issue":"13","key":"10.1016\/j.jnci.2016.04.003_b0035","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1200\/JCO.2001.19.13.3234","article-title":"Phase I study of anti\u2013epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer","volume":"19","author":"Robert","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jnci.2016.04.003_b0040","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jnci.2016.04.003_b0045","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ijrobp.2010.07.008","article-title":"Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer","volume":"81","author":"Koutcher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.jnci.2016.04.003_b0050","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.oraloncology.2014.08.005","article-title":"Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies","volume":"50","author":"Petrelli","year":"2014","journal-title":"Oral Oncol"},{"issue":"2","key":"10.1016\/j.jnci.2016.04.003_b0055","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jnci.2016.04.003_b0060","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4161\/cbt.9.5.10981","article-title":"Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck","volume":"9","author":"Rodr\u00edguez","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"27","key":"10.1016\/j.jnci.2016.04.003_b0065","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.jnci.2016.04.003_b0070","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2012.46.3299","article-title":"Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial","volume":"31","author":"Martins","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jnci.2016.04.003_b0075","doi-asserted-by":"crossref","first-page":"673","DOI":"10.4161\/cbt.10.7.12793","article-title":"Nimotuzumab with chemoradiation confers a survival advantage in treatment-na\u00efve head and neck tumors over expressing EGFR","volume":"10","author":"Basavaraj","year":"2010","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"10.1016\/j.jnci.2016.04.003_b0080","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","article-title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Mes\u00eda","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jnci.2016.04.003_b0085","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","author":"Magrini","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"8","key":"10.1016\/j.jnci.2016.04.003_b0090","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3109\/00016489.2015.1030772","article-title":"Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: a single-institution retrospective study in Japan","volume":"135","author":"Sakashita","year":"2015","journal-title":"Acta Otolaryngol"},{"issue":"7","key":"10.1016\/j.jnci.2016.04.003_b0095","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.oraloncology.2015.04.012","article-title":"Comparison of every 3 week cisplatin or weekly cetuximab with concurrent radiotherapy for locally advanced head and neck cancer","volume":"51","author":"Strom","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jnci.2016.04.003_b0100","article-title":"Toxicity of concomitant cetuximab and radiotherapy with or without initial taxane-based induction chemotherapy in locally advanced head and neck cancer","author":"Levy","year":"2015","journal-title":"Head Neck"},{"issue":"9","key":"10.1016\/j.jnci.2016.04.003_b0105","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s00066-014-0626-0","article-title":"Concurrent use of cisplatin or cetuximab with definitive radiotherapy for locally advanced head and neck squamous cell carcinomas","volume":"190","author":"Levy","year":"2014","journal-title":"Strahlenther Onkol"},{"issue":"5","key":"10.1016\/j.jnci.2016.04.003_b0110","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000355194","article-title":"Cisplatin versus cetuximab given concurrently with definitive radiation therapy for locally advanced head and neck squamous cell carcinoma","volume":"85","author":"Ley","year":"2013","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.003_b0115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/0284186X.2014.958528","article-title":"Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma","volume":"54","author":"Thomson","year":"2015","journal-title":"Acta Oncol"},{"issue":"10","key":"10.1016\/j.jnci.2016.04.003_b0120","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.oraloncology.2014.07.001","article-title":"Efficacy of concurrent cetuximab vs. 5-fluorouracil\/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC)","volume":"50","author":"Shapiro","year":"2014","journal-title":"Oral Oncol"},{"issue":"19","key":"10.1016\/j.jnci.2016.04.003_b0125","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1158\/1078-0432.CCR-14-0051","article-title":"Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: eastern cooperative oncology group trial E3303","volume":"20","author":"Egloff","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jnci.2016.04.003_b0130","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2014.00165","article-title":"Concurrent radiotherapy with Carboplatin and cetuximab for the treatment of medically compromised patients with locoregionally advanced head and neck squamous cell carcinoma","volume":"4","author":"Saigal","year":"2014","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jnci.2016.04.003_b0135","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1093\/annonc\/mdu248","article-title":"Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III\/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)","volume":"25","author":"Wanebo","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jnci.2016.04.003_b0140","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hed.23609","article-title":"Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer","volume":"37","author":"Tang","year":"2015","journal-title":"Head Neck"},{"issue":"7","key":"10.1016\/j.jnci.2016.04.003_b0145","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5s","key":"10.1016\/j.jnci.2016.04.003_b0150","volume":"32","author":"Ghi","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jnci.2016.04.003_b0155","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.6000","volume":"33","author":"Siu","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jnci.2016.04.003_b0160","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1200\/JCO.2015.63.1671","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","volume":"34","author":"Magrini","year":"2016","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.jnci.2016.04.003_b0165","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.1200\/JCO.2010.30.6423","article-title":"Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer","volume":"28","author":"Argiris","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jnci.2016.04.003_b0170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.2009.23.0425","article-title":"Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial","volume":"28","author":"Kies","year":"2010","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jnci.2016.04.003_b0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ijrobp.2015.10.019","article-title":"A phase 2 open label, single-arm trial to evaluate the combination of cetuximab plus taxotere, cisplatin, and 5-flurouracil as an induction regimen in patients with unresectable squamous cell carcinoma of the head and neck","volume":"94","author":"Mes\u00eda","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"27","key":"10.1016\/j.jnci.2016.04.003_b0180","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2009.22.1333","article-title":"Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck","volume":"27","author":"Haddad","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jnci.2016.04.003_b0185","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","article-title":"Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm","volume":"24","author":"Pfister","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Journal of the Egyptian National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036216300097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1110036216300097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T07:55:10Z","timestamp":1567842910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1110036216300097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S1110036216300097"],"URL":"https:\/\/doi.org\/10.1016\/j.jnci.2016.04.003","relation":{},"ISSN":["1110-0362"],"issn-type":[{"type":"print","value":"1110-0362"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti EGFR therapy in the treatment of non-metastatic head and neck squamous cell carcinoma: The current evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of the Egyptian National Cancer Institute","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jnci.2016.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Production and hosting by Elsevier B.V. on behalf of National Cancer Institute, Cairo University.","name":"copyright","label":"Copyright"}]}}